PLoS ONE · 2012 · 78 citations · 20 references
MedicineMolecular BiologyOncologyMolecular OncologyTumor HeterogeneityTumor ProgressionCancer Genomic InstabilityCancer ProgressionDna SequencingGenetic HeterogeneityNext-generation SequencingNext-generation Sequencing In OncologyCancer Heterogeneity AnalysisIntra-tumor HeterogeneityIntra-tumor Mutation DistributionTargeted Next-generation SequencingTp53 MutationsTumor Cell Population DynamicsTumor Cell Population StructureUltra-deep Sequencing
Human cancers are driven by the acquisition of somatic mutations. Separating the driving mutations from those that are random consequences of general genomic instability remains a challenge. New sequencing technology makes it possible to detect mutations that are present in only a minority of cells in a heterogeneous tumor population. We sought to leverage the power of ultra-deep sequencing to study various levels of tumor heterogeneity in the serial recurrences of a single glioblastoma multiforme patient. Our goal was to gain insight into the temporal succession of DNA base-level lesions by querying intra- and inter-tumoral cell populations in the same patient over time. We performed targeted "next-generation" sequencing on seven samples from the same patient: two foci within the primary tumor, two foci within an initial recurrence, two foci within a second recurrence, and normal blood. Our study reveals multiple levels of mutational heterogeneity. We found variable frequencies of specific EGFR, PIK3CA, PTEN, and TP53 base substitutions within individual tumor regions and across distinct regions within the same tumor. In addition, specific mutations emerge and disappear along the temporal spectrum from tumor at the time of diagnosis to second recurrence, demonstrating evolution during tumor progression. Our results shed light on the spatial and temporal complexity of brain tumors. As sequencing costs continue to decline and deep sequencing technology eventually moves into the clinic, this approach may provide guidance for treatment choices as we embark on the path to personalized cancer medicine.
20
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Roel G.W. Verhaak, Katherine A. Hoadley, Elizabeth Purdom et al. · Cancer Cell · 2010 · 7.7K citations · Full text
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons, Siân Jones, Xiaosong Zhang et al. · Science · 2008 · 5.8K citations · Full text